Envafolimab (CD274/PD-L1/B7-H1) - Research Grade Biosimilar

• Background:

  Envafolimab (KN035) is the first humanized anti-PD-L1 single domain antibody and new fusion protein of human IgG1 Fc. Compared with the PD-1/PD-L1 antibody that is currently on the market and under development, it has obvious advantages. . Envafolimab has the advantages of subcutaneous injection, stability at room temperature, and rapid tumor penetration, thereby improving the compliance of cancer patients with medication and improving the quality of life of patients. It is in line with the future trend of long-term management of cancer as a chronic disease.

• Immunogen:

  Chimeric / CD274/PD-L1/B7-H1 [Homo sapiens]

• Clonality:

  Recombinant Monoclonal

• Conjugation:

  Unconjugated

• Type:

  Primary Antibodies, Biosimilars

• Source:

  CHO cells

• Field of Research:

  Cancer, Immunology

• Purification:

  >95%

• Concentration:

  Batch dependent

• Buffer:

  PBS buffer pH7.5

• Modification:

  None

• Shipping Conditions:

  Blue Ice

• Storage Conditions:

  Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8 ˚ C for 1-2 weeks. Store at -20 ˚ C for 12 months. Store at -80 ˚ C for long term storage.

• Fragment:

  (VH-CH2-CH3) 2

• NCBI Organism:

  Homo sapiens

• Other Product Names:

  KN-035